openPR Logo
Press release

Gold Law Firm, LLC, the National Vaccine Injury Law Firm, files Vaccine Petition alleging Death Caused from Flu Vaccine

06-06-2016 03:16 PM CET | Politics, Law & Society

Press release from: Gold Law Firm, LLC.

Gold law Firm, LLC, the national vaccine injury law firm that handles vaccine injury claims exclusively, recently filed a vaccine petition for a 92-year old woman who had a severe reaction to the Influenza Vaccine resulting in an exacerbation of her Chronic inflammatory demyelinating polyneuropathy (CIDP), an acquired immune-mediated inflammatory disorder of the peripheral nervous system, which led to her death. The case, filed in the Court of Federal Claims in Washington, D.C., sought recovery under the National Vaccine Injury Compensation Program. 

“This case is a striking example of the injuries and adverse reactions that can occur as a result of vaccinations,” says Howard Gold, a leading Vaccine attorney.

According to the Centers for Disease Control and Prevention (CDC), the flu vaccine is designed to protect young and old alike from contracting the Flu, which can have devastating affects on the infirmed and elderly and can be debihlitating to otherwise healthy individuals, leading to more severe conditions, including Pneumonia. http://www.cdc.gov/flu/protect/keyfacts.htm

In this most recent case, 16-vv-650v. SECRETARY OF HEALTH AND HUMAN SERVICES, the Petitioner received the Flu Vaccine and shortly thereafter began to experience tingling and numbness in her lower extremities. She then went on to lose motor control and balance.  She was quickly diagnosed with CIDP which is a chronic form of Guillain-Barre' Syndrome.  She spent many months bedridden trying to breathe, walk and eat on her own. Unfortunately, she succumbed to her illness.    Guillain-Barre' and other reactions are continually reported to the Vaccine Adverse Events Reporting System (VAERS) as occuring after the Flu Vaccine. See, http://www.vaers.hhs.gov. “I strongly believe that children and adults alike should be receiving all of their mandatory vaccinations. However, it's important to talk to your health care practitioner about the risks of a vaccine injury,” states Gold, who has been handling Vaccine cases for 17 years.

Gold also says that there is nothing inherently wrong with the Flu Vaccine but that each person is different and reacts differently to each vaccination. That is why it's essential that the public be aware of a Program intended to compensate them if they do, in fact, have a reaction.

Petitioners have three (3) years from the onset of the injury (or two years from date of death) to file a claim. Gold states that the “Program is not used as much as it could be because the American public is just not aware of it. I receive at least 5 calls a month from individuals who cannot obtain compensation because the deadline has passed. They just found out about it too late. We all need to do a better job in getting the word out to the public that the Program exists.”

For more information on vaccine injury claims, contact  781-239-1000 or hgold@goldlawfirm.net or visit  usvaccinelaw.com

Howard Gold has been involved in the Vaccine Injury Program for more than twenty (20) years, assisting individuals and families across the United States. (Since he was a summer Law Clerk in the Vaccine Division at the U.S. Department of Justice in 1991!)
His unparalleled reputation for honesty, integrity and hard-work work helps ensure your matter is handled with care and competence.

83 Walnut Street
Suite 150
Wellesley Hills, MA 02481
tel: 7812391000
fax: 7814160930
email: hgold@goldlawfirm.net
www.usvaccinelaw.com
twitter: @usvaccine

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gold Law Firm, LLC, the National Vaccine Injury Law Firm, files Vaccine Petition alleging Death Caused from Flu Vaccine here

News-ID: 343406 • Views:

More Releases for Vaccine

Flu Vaccine (Influenza Vaccine) Market: A look into the future of the “Univers …
Latest update on Flu Vaccine (Influenza Vaccine) Market Analysis Report published with an SMI, the industry growth analysis, and Projection by 2021-2028. This report is highly predictive as it holds the overall market analysis of the topmost companies in the Flu Vaccine (Influenza Vaccine) industry. With the classified Flu Vaccine (Influenza Vaccine) market research based on various growing regions, this report provides leading players' portfolios along with sales, growth, market
Vaccine Market
Rise in the prevalence of infectious diseases, increase in immunization programs across the globe, and surge in R&D activities to develop new vaccine drive the growth of the global vaccine market. Global Vaccines Market was pegged at $32.46 billion in 2019, and is anticipated to hit $54.15 billion by 2027, registering a CAGR of 6.6% from 2020 to 2027. The report provides an in-depth analysis of the top investment pockets, top
US Flu Vaccine [Influenza Vaccine] Market Research Report 2020
DPI Research offers a latest published report on “Influenza Vaccines in the United States – Market Size, Trends, Opportunities and Growth Potential” delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key US flu vaccines market players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze
Measles Vaccine
Measles Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Measles Vaccine Market Production and Demand Analysis 2019 to 2025 Measles Vaccine Market 2019 Manufacturing Analysis and Development Forecast 2025 Measles Vaccine Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Measles Vaccine Market to Insight By 2025: Top Key Vendors The global Measles Vaccine market is valued at million US$ in 2018 and will reach million US$ by the
Monovalent vaccine segment to accumulate maximum Paediatric Vaccine Market share
According to a new report published by Future Market Insights titled “Paediatric Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026”, in terms of revenue, the global paediatric vaccine market is expected to increase at 12.2% CAGR during the forecast period 2016-2026. The global paediatric vaccine market is expected to reach US$ 27.97 Bn in 2016. Paediatric vaccine market is a billion dollar market accounting for a substantial proportion
Key Tools for Innovative Vaccine Designs: Vaccine Adjuvants
The report “NORTH AMERICA VACCINE ADJUVANTS MARKET” provides the detail description of market segmentation, applications, growth, size, and outlook. The market is projected to reach USD $278 Million by 2024, at a CAGR of 11.3%. An adjuvant is an immunological agent, which modifies the effect of other agents. Adjuvants can also act as an irritant, which engages and amplifies the body immune response. Adjuvants are added to vaccines to boost the